Enfortumab Vedotin in Patients With Locally Advanced or Metastatic Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy: a Multicenter, Phase II Investigator-initiated Trial (ENVELOPE, NCCH2412/MK015)
Latest Information Update: 23 Jan 2026
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ENVELOPE
Most Recent Events
- 23 Jan 2026 New trial record